The Geographic Atrophy therapeutics market is expected to grow significantly in the upcoming years owing to the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies, increasing prevalent patient pool, and a better understanding of pathophysiology.
“Geographic Atrophy Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Geographic Atrophy Market.
The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Geographic Atrophy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Geographic Atrophy and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Geographic Atrophy therapeutics market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight’s Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Recent Developments in the Geographic Atrophy Therapeutics Segment
• On September 19, 2022, Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX) announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD), also known as Geographic Atrophy. Furthermore, Pixium has added that the target number of 38 patients have been enrolled at clinical sites across countries such as France, Germany, the UK, the Netherlands, and Italy.
• On September 06, 2022, IVERIC bio, Inc. (Nasdaq: ISEE) declared positive topline results from GATHER2, the company’s second Phase 3 clinical trial evaluating its lead drug candidate Zimura® (avacincaptad pegol). Zimura® is a novel investigational complement C5 inhibitor developed for treating geographic atrophy (GA).
• On August 24, 2022, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) revealed top-line data at 24 months showing increased effects over time with intravitreal pegcetacoplan. Pegcetacoplan is an investigational, targeted C3 therapy in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Learn How the Ongoing Clinical & Commercial Activities will Affect the Geographic Atrophy Therapeutic Segment:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight
Geographic Atrophy Therapeutics Landscape
Currently, there are no approved treatments present for Geographic Atrophy. The Age-Related Eye Disease Study (AREDS) suggested that supplementing patients’ diet with vitamin C, vitamin E, beta-carotene, and zinc could significantly reduce the risk of progressing to advanced AMD, and sometimes low visual aids and counseling is also helpful. Several therapies which reached an advanced stage of development have already failed; however, several therapies are currently in the pipeline to prevent the progression of GA.
There are approx. 20+ key companies which are developing therapies for Geographic Atrophy. Currently, IVERIC bio. has its Geographic Atrophy drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Geographic Atrophy Therapeutic Market Include:
• Ionis Pharmaceuticals
• IVERIC bio
• Apellis Pharmaceuticals, Inc.
• NGM Biopharmaceuticals
• Annexon Inc.
• Genentech
• Alexion AstraZeneca Rare Disease
• ONL Therapeutics
• Alkeus Pharmaceuticals
• Regenerative Patch Technologies, LLC
• Astellas Pharma Inc
• Gemini Therapeutics
• Boehringer Ingelheim
• Cell Cure Neurosciences LTD
• Stealth BioTherapeutics Inc.
• Hemera Biosciences LLC
• Gyroscope Therapeutics Limited
• Eyevensys
• Nanoscope Therapeutics, Inc.
• Catalyst Biosciences
• Novartis
• Roche (Genentech)
• CellCure Neurosciences
And many others
As per DelveInsight, Geographic Atrophy (GA) therapeutics market dynamics are anticipated to change in the coming years owing to the rise in novel drug development activities and growth in healthcare spending worldwide.
Geographic Atrophy Emerging Drugs Covered in the report include:
• IONIS-FB-LRx: Ionis Pharmaceuticals
• Zimura: IVERIC bio
• Pegcetacoplan
• HMR59/AAVCAGsCD59
• Risuteganib
• Elamipretide
• ALK-001
• Palucorcel/CNTO 2476
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Geographic Atrophy Current Treatment Patterns
4. Geographic Atrophy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Geographic Atrophy Late Stage Products (Phase-III)
7. Geographic Atrophy Mid-Stage Products (Phase-II)
8. Geographic Atrophy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Geographic Atrophy Discontinued Products
13. Geographic Atrophy Product Profiles
14. Key Companies in the Geographic Atrophy Market
15. Key Products in the Geographic Atrophy Therapeutics Segment
16. Dormant and Discontinued Products
17. Geographic Atrophy Unmet Needs
18. Geographic Atrophy Future Perspectives
19. Geographic Atrophy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Ophthalmic Laser Devices Market
“Ophthalmic Laser Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Ophthalmic Laser Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Ophthalmic Laser Devices market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
